Bank of America Merrill Lynch Maintains Buy on Merck & Co.

Bank of America Merrill Lynch is out with its report today on Merck & Co. MRK, maintaining Buy. In a note to clients, Bank of America Merrill Lynch writes, "Merck offers a good mix of low valuation, track record of returning cash to shareholders, and pipeline optionality, in our view. We also like that MRK's Pharma revenue base is fairly diverse and is supplemented by animal health and consumer businesses, which we see as 'sticky' cash flow streams with growth potential." Bank of America Merrill Lynch maintains a $41 PO on MRK. Shares of MRK closed Monday at $35.56, down 0.73% from Friday's close.